We retrospectively investigated the relations of blood gas analysis results and serum markers such as KL-6 and ferritin before the beginning of treatment with outcome in DM-A/SIP patients who underwent early CSA/GC combination therapy and 2-hour postdose blood concentration (C2) monitoring. The gene discussed is MUC1; the disease is dermatomyositis.